{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T20:28:40Z","timestamp":1787776120679,"version":"build-2784847793"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,10]]},"abstract":"<jats:sec>\n                    <jats:title>Context:<\/jats:title>\n                    <jats:p>Therapeutic proteins can cause immune responses, which may have clinical implications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims:<\/jats:title>\n                    <jats:p>The aim of the study was to assess the immunogenicity of recombinant human follicle-stimulating hormone (r-hFSH), when used for controlled ovarian stimulation (COS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Settings and Design:<\/jats:title>\n                    <jats:p>Prospective, multicenter study conducted at reproductive medicine clinics in India and Vietnam.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>\n                      A total of 285 women, aged 20\u201340 years, undergoing 354 COS cycles for either intrauterine insemination (IUI) or\n                      <jats:italic toggle=\"yes\">in vitro<\/jats:italic>\n                      fertilization (IVF) were studied. The primary outcome measure was the incidence of development of anti-drug antibodies (ADA) and their neutralization potential. Other outcome measures were follicle development, dose and duration of r-hFSH, positive serum pregnancy test, clinical pregnancy, cycle cancellation, and adverse events (AEs).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Statistical Analysis Used:<\/jats:title>\n                    <jats:p>A sample size of 250 was planned. Descriptive statistics are presented.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Four patients tested positive for ADA after r-hFSH administration at different time points; all of them tested negative, subsequently. None were found to have neutralization potential. The mean dose and duration of r-hFSH were 816 IU and 8.1 days in IUI and 2183 IU and 9.5 days in IVF, respectively. The serum and clinical pregnancy rates were 12.4% and 11.6% in IUI and 32.7% and 29.9% in IVF cycles, respectively. Seven AEs were reported, including two cases of ovarian hyperstimulation syndrome; two AEs were judged to be serious.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The tested r-hFSH has very low immunogenic potential and did not lead to the development of neutralizing antibodies. The overall efficacy and safety of the drug were in-line with existing literature data, and no specific clinical impact of immunogenicity could be identified.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jhrs.jhrs_33_19","type":"journal-article","created":{"date-parts":[[2019,12,16]],"date-time":"2019-12-16T05:14:16Z","timestamp":1576473256000},"page":"303-309","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["A Multicenter Phase IV Study to Investigate the Immunogenicity of Recombinant Human Follicle-Stimulating Hormone and Its Impact on Clinical Outcomes in Females Undergoing Controlled Ovarian Stimulation"],"prefix":"10.4103","volume":"12","author":[{"given":"Abha","family":"Majumdar","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Sir Ganga Ram Hospital, New Delhi, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Le","family":"Hoang","sequence":"additional","affiliation":[{"name":"Center for Assisted Reproduction, National Hospital of Obstetrics and Gynecology, Hanoi, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ly T.","family":"Loc","sequence":"additional","affiliation":[{"name":"Infertility Department, Hung Vuong Hospital, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Padma","family":"Srivastava","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Inamdar Multispeciality Hospital, Pune, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chitra","family":"Ramamurthy","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Apollo Hospitals, Bengaluru, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ratnabali","family":"Chakravorty","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, ILS Hospitals, Kolkata, West Bengal, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogeshwar S.","family":"Nandanwar","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. D","family":"Rashmi","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Apollo BGS Hospitals, Mysore, Karnataka, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul V.","family":"Mayekar","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Lokmanya Tilak Municipal Medical College and General Hospital, Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Sridhar","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynaecology, Choithram Hospital and Research Centre, Indore, Madhya Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh H.","family":"Divekar","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Pharmacovigilance, Bharat Serums and Vaccines Limited, Navi Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"John","sequence":"additional","affiliation":[{"name":"Department of Clinical Research and Pharmacovigilance, Bharat Serums and Vaccines Limited, Navi Mumbai, Maharashtra, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,12,17]]},"reference":[{"key":"R1-20250521","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1007\/s11095-011-0523-5","article-title":"Immunogenicity of therapeutic proteins: The use of animal models","volume":"28","author":"Brinks","year":"2011","journal-title":"Pharm Res"},{"issue":"Suppl 6","key":"R2-20250521","doi-asserted-by":"crossref","first-page":"vi3","DOI":"10.1093\/ndt\/gfh1092","article-title":"Factors influencing the immunogenicity of therapeutic proteins","volume":"20","author":"Schellekens","year":"2005","journal-title":"Nephrol Dial Transplant"},{"key":"R3-20250521","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/aji.12675","article-title":"Assessment of the immunogenicity of gonadotrophins during controlled ovarian stimulation","volume":"78","author":"Morte","year":"2017","journal-title":"Am J Reprod Immunol"},{"key":"R4-20250521","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/psb.1108","article-title":"Introduction of biosimilars: Not to be confused with generics","volume":"24","author":"Mason","year":"2013","journal-title":"Prescriber"},{"key":"R5-20250521","article-title":"FDA\/CDER\/CBER. Assay Development and Validation for Immunogenicity Testing of Therapeutic Protein Products \u2013 Guidance for Industry","year":"2016","journal-title":"FDA"},{"key":"R6-20250521","article-title":"European Medicines Agency. Guideline on Immunogenicity Assessment of Biotechnology-Derived Therapeutic Proteins (EMEA\/CHMP\/BMWP\/14327\/2006)","year":"2007"},{"key":"R7-20250521","article-title":"FDA. Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins Guidance for Industry Assay Development for Immunogenicity Testing of Therapeutic Proteins","year":"2009","journal-title":"Draft Guid"},{"key":"R8-20250521","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.biologicals.2015.06.004","article-title":"Immunogenicity assessment of biotherapeutic products: An overview of assays and their utility","volume":"43","author":"Wadhwa","year":"2015","journal-title":"Biologicals"},{"key":"R9-20250521","first-page":"1","article-title":"Committee for Medicinal Products for Human Use. Guideline on Non-Clinical and Clinical Development of Similar Biological Medicinal Products Containing Recombinant Human Follicle Stimulating Hormone (r-hFSH). Guideline on Non-Clinical and Clinical Development of Similar Biological Medicinal Products Co","year":"2011","journal-title":"UK Eur Med Agency"},{"key":"R10-20250521","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/cei.12742","article-title":"From the bench to clinical practice: Understanding the challenges and uncertainties in immunogenicity testing for biopharmaceuticals","volume":"184","author":"Gunn","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"R11-20250521","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.reuma.2012.09.002","article-title":"Understanding the immunogenicity concept","volume":"9","author":"Valor","year":"2013","journal-title":"Reum Clin"},{"key":"R12-20250521","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/humrep\/dew075","article-title":"First line fertility treatment strategies regarding IUI and IVF require clinical evidence","volume":"31","author":"Bahadur","year":"2016","journal-title":"Hum Reprod"},{"key":"R13-20250521","doi-asserted-by":"crossref","first-page":"e109133","DOI":"10.1371\/journal.pone.0109133","article-title":"Effectiveness of gnRH antagonist in the management of subfertile couples undergoing controlled ovarian stimulation and intrauterine insemination: A meta-analysis","volume":"9","author":"Luo","year":"2014","journal-title":"PLoS One"},{"key":"R14-20250521","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1016\/j.fertnstert.2014.01.009","article-title":"Prognosis factors of pregnancy after intrauterine insemination with the husband's sperm: Conclusions of an analysis of 2,019 cycles","volume":"101","author":"Dinelli","year":"2014","journal-title":"Fertil Steril"},{"key":"R15-20250521","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4103\/jhrs.JHRS_34_18","article-title":"An intrauterine insemination audit at tertiary care hospital: A 4\u00bd years\u2019 retrospective analysis of 800 intrauterine insemination cycles","volume":"11","author":"Wadhwa","year":"2018","journal-title":"J Hum Reprod Sci"},{"key":"R16-20250521","first-page":"CD005354","article-title":"Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles","volume":"2","author":"van Wely","year":"2011","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Journal of Human Reproductive Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jhrs.JHRS_33_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:52:06Z","timestamp":1787773926000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jhrs.JHRS_33_19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":16,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.4103\/jhrs.jhrs_33_19","relation":{},"ISSN":["0974-1208","1998-4766"],"issn-type":[{"value":"0974-1208","type":"print"},{"value":"1998-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"2019-03-06","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}